Originally published In Press as doi:10.1074/jbc.M207128200 on September 3, 2002
J. Biol. Chem., Vol. 277, Issue 44, 41786-41794, November 1, 2002
Tapasin Interacts with the Membrane-spanning Domains of Both
TAP Subunits and Enhances the Structural Stability of TAP1·TAP2
Complexes*
Gayatri
Raghuraman,
Philip Edward
Lapinski, and
Malini
Raghavan
From the Department of Microbiology and Immunology, University of
Michigan Medical School, Ann Arbor, Michigan 48109-0620
Received for publication, July 16, 2002, and in revised form, August 18, 2002
 |
ABSTRACT |
The transporter associated with antigen
processing (TAP) proteins are involved in transport of peptides from
the cytosol into the endoplasmic reticulum. Two subunits, TAP1 and
TAP2, are necessary and sufficient for peptide binding and peptide
translocation across the endoplasmic reticulum membrane. TAP1 and TAP2
contain an N-terminal hydrophobic membrane-spanning region and a
C-terminal nucleotide binding domain. Tapasin is an endoplasmic
reticulum resident protein that has been found associated with the TAP
subunits and shown to increase expression levels of TAP. Here we
investigated TAP-tapasin interactions and their effects on TAP function
in insect cells. We show tapasin binding to both TAP1 and TAP2 and to
the corresponding nucleotide binding domain-exchanged chimeras as well
as to a truncated TAP1·TAP2 complex containing just the
membrane-spanning regions of TAP1 and TAP2. However, tapasin
interactions with either the truncated TAP construct containing just
the nucleotide binding domain are not observed. Tapasin is not required
for high affinity peptide binding to TAP1·TAP2 complexes, and in
fact, the presence of tapasin slightly reduces the affinity of TAP
complexes for peptides. However, at near physiological temperatures,
both tapasin and nucleotides stabilize the peptide binding site of
TAP1·TAP2 complexes against inactivation, and enhanced
thermostability of both TAP subunits is observed in the presence of
tapasin. The enhanced structural stability of TAP1·TAP2 complexes in
the presence of tapasin might explain the observations that tapasin
increases TAP protein expression levels in mammalian cells.
 |
INTRODUCTION |
Major histocompatibility complex
(MHC)1 class I molecules
are a complex of a heavy chain, a light chain
(
2-microglobulin), and a short peptide. Peptides bound
within a groove of the MHC class I heavy chain are presented to CD8 T
lymphocytes (1) for immune surveillance against intracellular pathogens
as well as some exogenous pathogens. Many class I-associated peptides are derived from proteasome-mediated proteolysis of cytosolic proteins.
These peptides are translocated across the endoplasmic reticulum (ER)
membrane by the transporter associated with antigen processing (TAP).
Subsequently, the peptides become bound to MHC class I heavy
chain-
2microglobulin complexes (1). The transport of
peptides is an essential step, and hence, TAP is a primary component of
the antigen presentation pathway (2, 3). Assembly of peptides with
newly synthesized class I molecules is assisted by many proteins. These
include calreticulin (a chaperone), ERp57 (a
thiol-dependent oxidoreductase), and tapasin. These
components together with TAP and the MHC class I subunits, constitute a
large complex called the "MHC class I peptide-loading complex" (4). Upon binding to peptides, class I molecules are released from the
assembly complex and transit to the cell surface (1).
TAP comprises two subunits, TAP1 and TAP2, both of which are required
for the transport function. Each subunit has one C-terminal nucleotide
binding domain (NBD) and one N-terminal transmembrane region with
several membrane-spanning domains (MSRs) (for review, see Refs. 2 and
3). TAP catalyzes transport of peptides across the ER membrane in an
ATP-dependent manner. A broad range of peptides (9-15
amino acids in length) is translocated by TAP (2, 3). The functions of
TAP can be broken down as (i) sequestration of antigenic peptides on
the cytosolic face of the ER membrane and (ii) binding and hydrolysis
of ATP, which powers translocation of peptides across the ER membrane.
At low temperatures, peptide binding to TAP does not require exogenous
ATP (5-7), but nucleotides are essential for maintaining TAP complex
stability at physiological temperatures (8). ATP is essential for
peptide translocation by TAP, and non-hydrolyzable ATP analogs do not
support peptide translocation (9).
Tapasin is an ER-resident 48-kDa transmembrane glycoprotein found
associated with TAP1·TAP2 complexes (10-12). Tapasin binds to TAP
through its transmembrane and/or cytosolic domains (13, 14). The
presence of tapasin in mammalian cells increases expression levels of
the TAP proteins (14), thus quantitatively increasing the amount of
peptide translocated by TAP complexes (13). Tapasin also interacts with
MHC class I molecules via residues in its N terminus (13). Optimal
peptide loading of many MHC class I molecules requires the presence of
tapasin (for review, see Ref. 15). The mechanisms by which tapasin
enhances MHC-peptide assembly have been suggested to be distinct from
the effect of tapasin on TAP function (14).
The goals of the analyses described here were to investigate the
interactions of tapasin with TAP subunits and domains, to study the
effects of tapasin on TAP functions in peptide binding and
translocation, and also to investigate the effect of tapasin on TAP
complex stability. Using insect cell-reconstituted proteins, we
analyzed binary interactions between tapasin and the TAP subunits and
domains. Our studies provide evidence for tapasin interactions with the
MSR of both TAP subunits and implicate tapasin in maintaining TAP
complex stability at physiological temperatures.
 |
EXPERIMENTAL PROCEDURES |
Baculoviruses for expression of, TAP1, TAP2, T1MT2C, T2MT1C, T1M,
T2M, T1Ctr, T2Ctr, TAP1-eGFP, and Tapasin--
Baculoviruses encoding
wild type TAP1 and TAP2 constructs were obtained from the Tampe lab
(16). Human TAP1 and TAP2 cDNAs for the other TAP constructs
described here were obtained from Dr. John Trowsdale. Baculovirus
constructs encoding the TAP chimeras (T1MT2C and T2MT1C) were
previously described and contain residues 1-541 of TAP1 and 507-686
of TAP2 (T1MT2C) and residues 1-506 of TAP2 and 542-748 of TAP1
(T2MT1C), respectively (17). Baculoviruses encoding the TAP
membrane-spanning domains were made as follows. T1M encodes residues
1-471 of TAP1, tagged with an AU1 epitope tag on the N terminus. T2M
encompasses residues 1-432 of TAP2, tagged with an AU5 epitope tag on
the N terminus. PCR was used to engineer both constructs. The 5'
primers contained a BamHI site and a sequence encoding the
AU1 tag and a BglII site and a sequence encoding the AU5 tag
for generating T1M and T2M, respectively. The 3' primers contained a
stop codon at the desired locations and BamHI (for T1M) and
BglII (for T2M) sites. The PCR products were ligated into
pPCRscript (Stratagene), sequenced, and then excised and ligated into
the BamHI and BglII sites of the baculovirus transfer vector pAcUW51 (Pharmingen), respectively. This vector was
co-transfected with BaculoGold DNA (Pharmingen) into insect cells as
described in the Pharmingen Baculovirus Expression Manual. Pure virus
was isolated using plaque assays and further amplified by re-infection.
TAP NBD constructs T1Ctr (residues 472-748 of TAP1) and T2Ctr
(residues 433-686 of TAP2) were made as described previously (18) but
in a single virus. T1Ctr has a C-terminal hexahistidine tag, whereas
the T2Ctr has a C-terminal Myc epitope tag. The T1Ctr-encoding
construct that had been ligated into the BamHI site of
pAcUW51 was excised and re-ligated into the BamHI site of
pAcUW51, which had the T2Ctr-encoding construct cloned into the
BglII site. Baculoviruses encoding both NBD constructs in a
single virus were generated using this vector.
The peptide translocation assays used an enhanced green fluorescent
protein-tagged version of TAP1 (TAP1-eGFP). The TAP1-eGFP fusion was
constructed by bridge PCR. The first PCR amplified the TAP1 portion of
the fusion construct using a 5' primer with a BamHI site
followed by a sequence complementary to the 5' end of TAP1 and a 3'
primer with the last 15 nucleotides of the TAP1 sequence and the first
15 nucleotides of the eGFP sequence. The eGFP template was obtained
from the pEGFP plasmid (Clontech). The second PCR
used a 5' primer that was complementary to the 3' primer used for TAP1
amplification and a 3' primer complementary to the 3' end of the eGFP
sequence followed by a BamHI site. Both these PCR products
were gel-extracted and used as templates for a third PCR, which used
the 5' primer of the TAP1 PCR and the 3' primer of the eGFP PCR. This
bridge PCR product was gel-extracted, ligated into pPCRScript
(Stratagene), and sequenced. The TAP1-eGFP fusion was then ligated into
pAcUW51 (Pharmingen), which was used to generate virus.
Human tapasin cDNA was obtained from Dr. Ping Wang (10). PCR was
used to introduce BamHI sites on the 5' and 3' ends. The modified cDNA was ligated into pPCRscript, sequenced, and cloned into the BamHI site of the pAcUW51 vector. Recombinant
baculoviruses were generated as described above.
Metabolic Labeling and Co-immunoprecipitation
Analyses--
Cells were infected with multiple baculoviruses at
multiplicity of infection levels between 1 and 80, established to
optimize expression levels of proteins that were being analyzed. After 60 h of infection, the supernatants were removed and replaced with
2.5 ml of Grace's insect medium without L-methionine
(Invitrogen) but containing 105 µCi of 35S-labeled
methionine/cysteine (ICN). After incubation at 26 °C for 45 min, 3.5 ml of methionine-free Grace's medium supplemented with 10% dialyzed
fetal bovine serum was added, and cells were incubated overnight at
26 °C. For immunoprecipitations, cells were lysed on ice in 1 ml of
lysis buffer (10 mM phosphate buffer, 10 mM
Tris, 130 mM NaCl, 1% digitonin, pH 7.5)
containing a protease inhibitor mixture (1 mM
phenylmethylsulfonyl fluoride, 0.308 µM aprotinin, 10.5 µM leupeptin, 10 µM pepstatin, 1 mM benzamidine) for 1 h. Immunoprecipitation protocols
were similar to those previously described (6, 18). The antibodies used
in the present analyses were anti-TAP1 antiserum (19), anti-TAP2
antiserum (19), anti-His (Covance Scientific), anti-Myc (9E10),
anti-AU1 (Covance Scientific), anti-AU5 (Covance Scientific),
anti-tapasin (Rgp48C (13)), a control
anti-
2microglobulin antibody (Roche Diagnostics), or a
control antibody directed against glycoprotein H of herpes simplex virus (52-S, ATCC). Wild type TAP1 (TAP1) and wild type TAP2 (TAP2) are
recognized by the anti-TAP1 and anti-TAP2 antisera respectively, which
were generated against C-terminal (NBD) epitopes of TAP1 and TAP2
(19). Tapasin is recognized by an anti-tapasin antibody (13) raised
against residues in the cytosolic domain of tapasin. T1MT2C is
recognized by the anti-TAP2 antiserum (17). T2MT1C is recognized by
anti-TAP1 antiserum and also by an anti-His antibody (17) due to the
presence of a C-terminal histidine tag.
Preparations of Microsomes, Immunoblotting Analyses, Peptide
Translocation Assays, and Fluorescent Peptide-based Binding
Assays--
Cells were infected with appropriate baculoviruses (TAP1,
TAP2 or TAP1, TAP2, tapasin) at multiplicity of infection values of
1-80 depending on the desired protein expression levels. To achieve
equal levels of expression of TAP subunits in the presence or absence
of tapasin, the multiplicity of infection values were typically lower
for the TAP viruses when co-infected with the tapasin virus compared
with that used in the TAP virus infections alone. Protocols for
microsome preparations were similar to those described by Meyer
et al. (16). TAP and tapasin expression in the microsomes
was verified by immunoblotting analyses of the microsome preparations
(6). For this analysis, membranes were incubated in 15 ml of antibody
buffer containing 50 µl of 148.3 hybridoma supernatant (16), 10 µl
of 435.3 ascites fluid (20), and 7 µl of anti-tapasin antiserum (13).
Iodinated peptide-based translocation experiments with the model
peptide RR[125I]YNASTEL were performed exactly as
described (6). The peptide binding assays with fluorescent peptides
first described by Neumann and Tampe (21) were carried out using
procedures established in our laboratory with the model fluorescent
peptide RRYQKCFITCTEL (6).
Peptide Binding Assay by Inhibition Analyses--
Different
concentrations of the inhibitor peptides (5 nM to 500 µM) were mixed with a known concentration (40 nM) of RRYQKCFITCTEL, and the fluorescence
emission signal was allowed to stabilize. 20 µl of microsomes
expressing either TAP1·TAP2 or TAP1·TAP2-tapasin were added, and
the decrease in fluorescence signal was monitored until the signal
stabilized. The magnitude of quenching was calculated as described (6).
Fluorescence quenching was also monitored in the absence of added
inhibitor peptide. The magnitude of the quenching signal was plotted as
a function of the logarithm of the inhibitor peptide concentration.
EC50 values were obtained by fitting the curve to a
one-site competition equation using GraphPad Prism software.
Thermolability of the TAP Peptide Binding Site--
Microsomes
expressing TAP1·TAP2 or TAP1·TAP2-tapasin were incubated for 1 h at 34 or 4 °C after which both sets of microsomes were incubated
for 15 min on ice. Both sets of microsomes were tested for their
ability to quench the fluorescence of 40 nM
RRYQKCFITCTEL by estimating the quenching amplitudes.
Similar sets of analyses were carried out in the absence of
added exogenous nucleotide, or in the presence of 1 mM ATP,
or 1 mM ADP, or 0.03 units/µl apyrase. Data were analyzed
in two different ways. For each set of microsomes at 34 and 4 °C,
the ratios of the quenching amplitudes in the presence of ATP relative
to those obtained in the presence of no nucleotide, ADP, and apyrase
were calculated. Second, for each nucleotide condition, the ratio of
the quenching amplitude obtained at 34 °C was calculated relative to
that obtained at 4 °C.
Thermostability of TAP Subunits and Complexes in the Presence or
Absence of Tapasin--
Cells infected with baculoviruses encoding
TAP1eGFP, TAP2 or TAP1eGFP, TAP2, tapasin combinations were labeled
with [35S]methionine/cysteine (ICN) 60 h
post-infection as described above. 72 h post-infection, cells were
harvested, washed with phosphate-buffered saline, and incubated for
1 h at 4 or 34 °C in peptide binding assay buffer (5 mM dithiothreitol in phosphate-buffered saline, pH 7.4).
Lysis of the cells was carried out in 1% digitonin for 1 h.
Proteins were immunoprecipitated with anti-TAP2 or anti-tapasin antisera as described above or with anti-GFP (Covance Scientific; 1 µl/immunoprecipitation). A control antibody (anti-Myc) was also used
for the TAP1-eGFP·TAP2 infections. Samples were separated by SDS-PAGE
followed by phosphorimaging analyses. The intensity of the bands
corresponding to the TAP1-eGFP, TAP2, and tapasin were quantified using
ImageQuant software. Ratios of the relative intensities of TAP1 at 4 and 34 °C were quantified for the anti-GFP and anti-tapasin-based
immunoprecipitations. Ratios of the relative intensities of TAP2 at 4 and 34 °C were quantified for the anti-TAP2 and anti-tapasin-based immunoprecipitations.
 |
RESULTS |
Interactions of Tapasin with TAP Subunits, Chimeras, and Truncated
TAP Constructs--
Metabolic labeling experiments were carried out to
assess complex formation between TAP subunits or chimeras and tapasin. We infected Sf21 cells with baculoviruses encoding
TAP subunits (TAP1, TAP2) or chimeras T1MT2C (which encodes the MSR of
TAP1 and NBD of TAP2) and T2MT1C (which encodes the MSR of TAP2 and NBD
of TAP1) in combination with tapasin. To establish complex formation
between TAP subunits and tapasin, digitonin lysates of metabolically
labeled cells from the different infections were immunoprecipitated
with antibodies directed against the TAP subunit, tapasin, or an
irrelevant antibody control. Cells were lysed in 1% digitonin because
interactions between TAP and tapasin are weak and are unstable in other
detergents (12). Proteins were immunoprecipitated from lysates using
appropriate antibodies and separated by SDS-PAGE, and associating
proteins were visualized. TAP-tapasin interactions could be best
visualized by immunoprecipitations with an antiserum directed against
residues in the cytoplasmic domain of tapasin (13) (Fig.
1, A-D, lane 3).
In general, the anti-TAP antisera-based immunoprecipitations were more
difficult to assess due to the presence of nonspecific bands that
co-migrated in the vicinity of tapasin (Fig. 1, A-C,
lane 5; highlighted with asterisks).

View larger version (73K):
[in this window]
[in a new window]
|
Fig. 1.
Interactions of tapasin with TAP
subunits. Lysates from metabolically labeled cells infected with
viruses encoding the indicated TAP construct (lanes 1 and
5), the TAP construct and tapasin (lanes 3,
4, and 6), or tapasin alone (lane 2)
were immunoprecipitated with an antibody against tapasin (lanes
1-3), antibodies against TAP, (lanes 4 and
5), or a control 2-microglobulin-specific
antibody (lane 6). Co-immunoprecipitating proteins were
visualized by SDS-PAGE and phosphorimaging analysis. The anti-TAP
antibodies were anti-TAP1 antiserum (A), anti-TAP2 antiserum
(B and C), and anti-His antibody (D).
The results are representative of at least two independent sets of
analyses for each interaction.
|
|
We observed that TAP1 co-immunoprecipitated with tapasin in analyses
with the anti-tapasin antibody (Fig. 1A, lane 3 (co-infection) compared with lane 2 (single infection with
tapasin-encoding virus)). A nonspecific band (labeled as such) was also
observed in all the immunoprecipitations with the anti-tapasin
antibody. T1MT2C interaction with tapasin could also be visualized by
the anti-tapasin immunoprecipitations (Fig. 1B; lane
3 (co-infection) compared with lane 2 (single infection
with tapasin-encoding virus)), although the presence of a band
corresponding to T1MT2C in the control lanes 1 and
6 suggests that there may be a low level of nonspecific precipitation of T1MT2C. Complex formation between TAP2 and tapasin was
apparent in the analysis shown in Fig. 1C by
immunoprecipitations with both anti-tapasin (Fig. 1C,
lane 3 (co-infection) compared with lane 2 (single infection with tapasin-encoding virus)) and anti-TAP2 antisera
(Fig. 1C, lane 4 (co-infection) compared with lane 5 (single infection with TAP2)). Likewise, complex
formation between T2MT1C and tapasin was apparent in
immunoprecipitations with both anti-tapasin (Fig. 1D,
lane 3 (co-infection) compared with lane 2 (single infection with tapasin-encoding virus)) and anti-his antibodies
(Fig. 1D, lane 4 (co-infection) compared with lane 5 (single infection with T2MT1C)).
To study the association of the MSRs or NBDs of the TAP subunits with
tapasin, constructs encoding TAP membrane-spanning domains (T1M and
T2M, respectively, of TAP1 and TAP2) alone or NBDs alone (T1Ctr and
T2Ctr, respectively, of TAP1 and TAP2) were generated. The NBD
constructs have been previously described (18). The construct with the
TAP1 transmembrane regions (T1M) has an AU1 epitope at its N terminus
and can be recognized by an anti-AU1 antibody. The TAP2 counterpart
(T2M) has an N-terminal AU5 tag that can be recognized by an anti-AU5
antibody. Co-immunoprecipitation analyses with anti-AU1 and anti-AU5
antibodies of cells infected with a baculovirus encoding both T1M and
T2M revealed the presence of 2 proteins of ~40 kDa (Fig.
2A, lanes 1 and
2). Based upon the expected size, we predicted that the
larger protein was T1M. Consistent with this expectation, more of the
higher molecular weight protein was visualized in the AU1
immunoprecipitations compared with the AU5 immunoprecipitations.
Co-immunoprecipitation analyses suggested that both T1M and T2M
associated and that T2M was expressed in excess relative to T1M (Fig.
2A, lanes 1 and 2). Thus, the
membrane-spanning domains of TAP1 and TAP2 associate even in the
absence of the NBD, consistent with previous observations implicating
membrane-spanning residues of TAP1 and TAP2 in the TAP1·TAP2
interaction interface (22). By contrast, the TAP NBDs do not form
stable complexes under the conditions of these assays as previously
demonstrated (Fig. 2A, lanes 2 and 3)
(18).

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 2.
Interactions of tapasin with truncated TAP
constructs. Analyses were carried out as described in Fig. 1 but
assessed the following sets of interactions. A, TAP1·TAP2
MSR and NBD associations. Cells were infected with viruses encoding
T1M/T2M (MSRs of TAP1 and TAP2) (lanes 1 and 2)
or T1Ctr/T2Ctr (NBDs of TAP1 and TAP2) (lanes 3 and
4). Triton lysates were immunoprecipitated (IP)
with anti-AU1 (lane 1), anti-AU5 (lane 2),
anti-His (lane 3), and anti-Myc (lane 4).
Association of MSRs of TAP1 and TAP2 was observable (lanes 1 and 2), whereas no such association was observable with the
NBDs of TAP subunits (lanes 3 and 4).
B, interaction of MSRs of TAP with tapasin. Digitonin
lysates from metabolically labeled cells infected with viruses encoding
T1M/T2M and tapasin (lanes 1-4) were immunoprecipitated
with anti-AU1 (lane 1), anti-AU5 (lane 2),
anti-tapasin antiserum (lane 3), or a control antibody
(lane 4). T1M/T2M-tapasin interactions were visualized in
the anti-tapasin-based immunoprecipitations and to a lower extent in
the anti-AU1 and anti-AU5-based immunoprecipitations. C,
interaction of NBDs of TAP with tapasin. Digitonin lysates from
metabolically labeled cells infected with viruses encoding T1Ctr/T2Ctr
and tapasin (lanes 1-4) were immunoprecipitated with
anti-His (lane 1), anti-Myc (lane 2),
anti-tapasin antiserum (lane 3), or a control antibody
(lane 4). T1Ctr, T2Ctr, and tapasin do not associate as seen
from anti-TAP and anti-tapasin immunoprecipitations (lanes
1-3).
|
|
To investigate interactions of TAP MSRs and NBDs with tapasin, cells
were co-infected with baculoviruses encoding tapasin along with viruses
encoding the TAP MSR (T1M/T2M) or NBD (T1Ctr/T2Ctr). Metabolically
labeled cells were immunoprecipitated with anti-AU1, anti-AU5,
anti-tapasin, or irrelevant antibodies for MSR interactions with
tapasin or with anti-His, anti-Myc, anti-tapasin, or irrelevant antibodies for NBD interactions with tapasin. For the former set of
experiments, the anti-tapasin immunoprecipitation revealed tapasin and
T2M as well as a faint signal for T1M, indicative of complex formation
(Fig. 2B, lane 3). The low signal for T1M compared with T2M is likely due to the reduced expression of T1M relative to T2M. The ratio of T1M/T2M intensities in the anti-tapasin immunoprecipitation was roughly in proportion to the levels at which
the proteins were expressed. Tapasin-specific signals were also
visualized in the anti-AU1 and anti-AU5-based immunoprecipitations. By
contrast to the detectable interaction between T1M/T2M and tapasin,
binding was not observable between either T1Ctr and tapasin and/or
T2Ctr and tapasin in immunoprecipitations with anti-His, anti-Myc, or
anti-tapasin antibodies (Fig. 2C, lanes 1-3,
respectively). Our observations that T1Ctr and T2Ctr cannot be
co-immunoprecipitated with tapasin do not preclude the possibility that
TAP NBD residues of intact TAP1·TAP2 complexes participate in
TAP-tapasin interactions; rather, our data suggest that residues
contained in TAP1 and TAP2 NBD are not sufficient to mediate stable
binding to tapasin under the conditions of the analyses (Fig.
2C). Because T2Ctr in particular is quite unstable in
solution,2 we cannot exclude
the formal possibility that folding constraints in the NBD account for
the lack of observable interactions with tapasin.
The Peptide Binding Affinity of TAP1·TAP2 Complexes Is Slightly
Reduced in the Presence of Tapasin--
Tapasin-deficient 721.220 cells, when transfected with tapasin, show increased steady state
levels of the TAP1 protein (14). This increase in TAP expression level
quantitatively enhanced the amount of peptide translocated without
increasing the intrinsic rate of peptide translocation (13). To verify
this result in an insect cell-reconstituted system, we generated
microsomes expressing TAP1·TAP2 alone or TAP1·TAP2-tapasin such
that the TAP protein levels were approximately the same in the presence
or absence of tapasin. Conditions for obtaining maximal tapasin
expression were first optimized, and multiplicity of infection values
for TAP virus infections were subsequently optimized. An exact
correspondence of TAP expression levels in the presence and absence of
tapasin was difficult to achieve, although generally, the expression
levels of at least one of the TAP components was matched (Fig.
3A). Under these conditions,
we observed that the presence of tapasin did not significantly affect
the peptide translocation efficiency, as assessed by the established
peptide translocation assay (Fig. 3B) (9, 16, 20). Using a
similar translocation assay, we previously described mutant TAP
complexes as well as chimeric TAP complexes that were reduced in
translocation efficiency when compared with wild type (6, 17),
presumably due to changes in their ATPase activities. Thus, the assay
itself is sensitive enough to detect changes in translocation rates,
had tapasin effected changes in the rate.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Peptide translocation by TAP1-eGFP·TAP2 or
TAP1-eGFP·TAP2-tapasin microsomes under conditions of similar TAP
protein expression levels. A, expression of TAP1-eGFP,
TAP2, and tapasin in baculovirus-infected or uninfected cells.
Cells were infected with viruses encoding TAP1-eGFP and TAP2
(lane 2) or the same viruses as well as tapasin (lane
3). Microsome preparation from uninfected (lane 1) or
infected cells (lanes 2 and 3) were subject to
immunoblotting analyses with the indicated antibodies. B,
peptide translocation by TAP1-eGFP·TAP2 and TAP1-eGFP·TAP2-tapasin.
Microsomes containing the indicated proteins were assessed based upon
the ability to import 125I-labeled RRYNASTEL as previously
described (6). No significant differences in the translocation
efficiencies were apparent in the presence or absence of tapasin. The
data are representative of at least three independent analyses.
|
|
We also investigated the effects of tapasin on peptide binding to TAP
complexes. In the absence of tapasin, TAP1·TAP2 complexes expressed
in insect cells bind peptides with high affinity, an observation that
suggests tapasin is not essential for high affinity peptide binding by
TAP1·TAP2 complexes (6, 20, 21). Other investigations of TAP-specific
peptide binding to 721.220 (tapasin-deficient) membranes compared with
721.221 (tapasin-expressing) membranes or to 721.220 membranes that
were transfected with tapasin revealed a higher level of peptide
cross-linking to 721.221 microsomes compared with 721.220 microsomes
(14, 23), which is likely to reflect the higher expression levels of
the TAP proteins in the presence of tapasin. Analysis of the ability of
different concentrations of an ovalbumin-derived peptide, SIYNFEKL, to
inhibit binding of a cross-linker-modified and 125I-labeled
variant of the same peptide indicated that significantly lower
concentrations of unlabeled peptide were required to completely inhibit
photocross-linking in 721.220 microsomes compared with 721.221 microsomes (23). These results were previously interpreted as
indicating a lower peptide binding affinity in the absence of tapasin
(23). However, the results suggested to us that the presence of tapasin
might in fact decrease rather than increase the affinities of
peptide-TAP complexes. We therefore undertook a careful quantitative
analysis of peptide binding affinities of TAP1·TAP2 complexes
compared with TAP1·TAP2-tapasin complexes.
To investigate the relative peptide binding affinities of TAP1·TAP2
complexes compared with TAP1·TAP2-tapasin complexes, we again
generated two sets of microsomes expressing TAP1·TAP2 alone or
TAP1·TAP2-tapasin with protein expression levels similar to that
shown in Fig. 3A. We used a fluorescence quenching-based binding assay (21) in the absence of added exogenous nucleotides to
compare peptide binding to TAP1·TAP2 complexes in the presence or
absence of tapasin. For this assay, the model peptide RRYQKCTEL labeled
with fluorescein at the cysteine residue (RRYQKCFITCTEL) was used (6). Microsome preparations containing TAP1·TAP2 or TAP1·TAP2-tapasin were added to increasing concentrations of
RRYQKCFITCTEL, and the fluorescence emission signal was
monitored as a function of time. Unlabeled peptide was added to the
reaction mixes, and the recovery of fluorescence was also monitored
over time as the bound fluorescent peptide dissociated from TAP. The
apparent binding constants (KD) for peptide binding
by TAP1·TAP2 and TAP1·TAP2-tapasin were obtained by plotting steady
state fluorescence quenching signals as a function of peptide
concentration (Fig. 4A).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4.
Peptide binding to TAP1·TAP2 or
TAP1·TAP2-tapasin microsomes. A, RRYQKCFITCTEL
binding to TAP1·TAP2 and TAP1·TAP2-tapasin complexes at 25 °C.
Microsomal membranes expressing the indicated TAP complexes were added
to varying concentrations of RRYQKCFITCTEL (5-60
nM), and the steady state fluorescence quenching signals
were plotted as a function of peptide concentration to estimate binding
constants. The data for TAP1·TAP2 are a representative example from
two independent experiments using two different microsome preparations
in the present set of analyses, results of which were similar to the
previously reported binding data (6, 17). The data for
TAP1·TAP2-tapasin complexes are a representative example from at
least three independent experiments using different microsome
preparations. B, binding of VMAPCTLLL to TAP1·TAP2 and
TAP1·TAP2-tapasin assayed by inhibition analyses. To 40 nM RRYQKCFITCTEL were mixed increasing
concentrations of the inhibitor peptide VMAPCTLLL (5 to 500 µM), and the magnitudes of the quenching signals was
estimated upon the addition of TAP1·TAP2 or TAP1·TAP2-tapasin
microsomes. A plot of the quenching amplitudes versus
logarithm of VMAPCTLLL concentration allowed for the indicated
EC50 values to be derived. Data are representative of four
independent analyses, each with TAP1·TAP2 and TAP1·TAP2-tapasin
microsomes.
|
|
Analyses of the relative binding affinities of peptides of TAP1·TAP2
complexes in the presence or absence of tapasin indicated that tapasin
slightly reduced the peptide binding affinity of the TAP1·TAP2
complex. In parallel sets of analyses, we observed a 2-fold reduction
in the affinity calculated for TAP1·TAP2-tapasin complexes
(KD = 50.4 ± 5.05 nM; average of
three experiments) compared with TAP1·TAP2 complexes
(KD = 24.3 ± 2.4 nM, average of
two experiments in the present analyses; we previously reported room
temperature peptide binding constants of 14.4 ± 11 nM
for TAP1·TAP2 complexes in the absence of exogenous nucleotides (17)
and 19.4 ± 4.8 nM for TAP1·TAP2 complexes in the
presence of apyrase (6), which were derived from sets of analyses
independent from the data described here). Consistent with the observed
affinity reduction, the calculated dissociation rates were generally
higher for TAP1·TAP2-tapasin (kd = 0.015 ± 0.002 s
1) complexes compared with TAP1·TAP2
(kd = 0.009 ± 0.002 s
1)
complexes. However, because the standard deviations on the previously reported kd values for TAP1·TAP2 complexes were
relatively high (6, 17), the effect of tapasin on the dissociation rate was more difficult to assess than its effect on the derived
KD value.
The observation that RRYQKCFITCTEL bound TAP with ~2-fold
reduced affinity in the presence of tapasin raised the question of
whether the presence of tapasin enhanced or reduced the binding affinities of other peptides, in particular of peptides with lower affinities for TAP complexes. To address this question, a variety of
MHC class I binding peptides with the sequences VMAPRTLLL
(HLA-E-specific), VEITPYKPTW (HLA-B44-specific), and LLDVPTAAV
(HLA-A2-specific) were cysteine-substituted at position 4 or 5 of their
sequences and fluorescently labeled, and their binding to TAP was
assessed by the quenching assay. The labeled sequences were
VMAPCFITCTLLL, VEICFITCPYKPTW, and
LLDCFITCPTAAV. Fluorescence quenching was not observed with
any of these peptides upon addition of TAP-containing microsomes,
indicating that these peptides either did not bind to TAP complexes
with appreciable affinity, or that the environment of the fluorophores
in the bound peptides were not significantly different from that in the
free peptide. To distinguish these possibilities, the ability of
the corresponding unlabeled peptides to interact with TAP1·TAP2
complexes was assessed by investigating whether unlabeled peptides
could inhibit binding of RRYQKCFITCTEL to TAP1·TAP2
complexes. Of all the peptides tested, only VMAPCTLLL appeared to bind
to TAP complexes with an affinity higher than 50 µM. Very
high concentrations of the other peptides were required to observe a
50% reduction in RRYQKCFITCTEL-quenching signal (
50 µM for VEICPYKPTW and
100 µM for LLDCPTAAV).
Because the fluorescence of VMAPCFITCTLLL was not quenched
by TAP binding, we used an inhibition-based assay to study the effect
of tapasin on the binding of unlabeled VMAPCTLLL to TAP complexes.
Representative inhibition plots, one each for TAP1·TAP2 and TAP1·TAP2-tapasin complexes, are shown in Fig. 4B.
EC50 (concentration of VMAPCTLLL required to bring about
50% inhibition of the RRYQKCFITCTEL-quenching signals)
values were obtained by fitting the data to a one-site competition
equation using Graph Pad Prism software. The EC50 values
derived for TAP1·TAP2-tapasin were again about 2-fold higher than
that of TAP1·TAP2 when present alone. The mean EC50
values from multiple independent experiments are estimated to be
1504 ± 185 nM for TAP1·TAP2 complexes compared with
3009 ± 304 nM for TAP1·TAP2-tapasin complexes.
KD calculations using the formula
KD = EC50/(1+[RRYQKCFITCTEL])/KD[RRYQKCFITCTEL] (24) indicated that the affinity for VMAPCTLLL binding to TAP1·TAP2 (average KD ~ 915 nM) was about 4-fold
higher than for VMAPCTLLL binding to TAP1·TAP2-tapasin (average
KD ~ 3700 nM). Taken together, these
observations emphasize that tapasin is not required for high affinity
peptide binding by TAP1·TAP2 complexes and that in fact tapasin may
slightly reduce the binding affinities of TAP complexes for peptides.
Effect of Tapasin on TAP Complex Stability in the Absence and
Presence of Nucleotides--
Tapasin increases TAP expression levels
in mammalian cells that could arise from its effect on TAP complex
stability at physiological temperatures (14, 25). We wanted to use an
in vitro assay to investigate the effect of tapasin on TAP
complex stability at near physiological temperatures. TAP1·TAP2
complex formation is required to create a high affinity peptide binding
site, and the structural integrity of the peptide binding site can thus be used as a measure of the structural integrity of the TAP complex. It
has been shown that human TAP proteins undergo structural changes when
incubated to 37 °C that lead to a complete loss of peptide binding
function. The presence of nucleotide diphosphates or triphosphates was
found to stabilize the TAP complex against inactivation of peptide
binding function at 37 °C (8). We studied the effect of tapasin in
stabilizing the TAP heterodimer against heat-induced inactivation and
compared the effects of tapasin and nucleotides in rendering stability
to TAP1·TAP2 complexes (Fig. 5).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of tapasin and nucleotides on the
thermostability of the peptide binding site of TAP1·TAP2
complexes. Stability was assessed by measuring the ability of TAP
complexes to retain peptide binding function (after the indicated
incubations) using the RRYQKCFITCTEL-based quenching assay.
Experiments were carried with microsomes incubated for 1 h at 34 or at 4 °C. A, for each set of microsomes incubated at 4 and 34 °C, the quenching signals obtained in the absence or
exogenous nucleotide, in the presence of ADP, and in the presence of
apyrase are plotted as ratios of the corresponding signals obtained in
the presence of 1 mM ATP. The values are averages from five
independent experiments using four different microsome preparations,
each experiment performed in duplicate. B, the ratios of the
quenching signals at 34 °C relative to those obtained in the 4 °C
incubations were calculated for each nucleotide condition. TAP1·TAP2
and TAP1·TAP2-tapasin microsomes are compared.
|
|
Microsomes expressing TAP1·TAP2 or TAP1·TAP2-tapasin were incubated
at 34 °C for 1 h followed by incubation for 15 min on ice.
These microsomes as well as untreated microsomes (4 °C treated microsomes) were tested for their ability to bind peptides using the
fluorescence quenching-based assay. To illustrate the effects of
nucleotides on maintaining the stability of TAP1·TAP2 and
TAP1·TAP2-tapasin complexes, the quenching signals obtained in the
presence of no added nucleotide, ADP, or apyrase were normalized
relative to the signals that were obtained in the presence of ATP (Fig.
5A). Both ATP and ADP stabilized TAP complexes against
inactivation of their peptide binding functions at 34 °C as
previously described (7, 8), with ATP being slightly more optimal under
some conditions. Setting the quenching signals obtained in the presence of ATP at 1, the relative signals obtained in the presence of ADP,
apyrase, or no exogenous nucleotides were compared. For TAP1·TAP2 complexes stored at 4 °C, the relative signals were 0.72 ± 0.25 if no exogenous nucleotide was added, 0.94 ± 0.19 in the
presence of ADP, and 0.54 ± 0.16 when microsomes were treated
with apyrase. After the 34 °C incubation, however, the signals for
TAP1·TAP2 complexes were 0.04 ± 0.04 if no exogenous nucleotide
was added, 0.72 ± 0.18 in the presence of ADP, and 0.16 ± 0.06 when microsomes were treated with apyrase. For TAP1·TAP2-tapasin
complexes stored at 4 °C before the peptide binding assays, the
relative signals were 1.03 ± 0.21 if no exogenous nucleotide was
added, 1.16 ± 0.29 in the presence of ADP, and 0.56 ± 0.10 when treated with apyrase. For TAP1·TAP2 complexes incubated at
34 °C before the peptide binding assays, the relative signals were
0.54 ± 0.07 if no exogenous nucleotide was added, 0.82 ± 0.22 in the presence of ADP, and 0.28 ± 0.10 when microsomes were
treated with apyrase. We previously showed that at room temperature the
peptide binding affinities and dissociation kinetics were very similar
for TAP complexes in the presence of ADP or apyrase, and similar
KD and kd values were also
observed in the presence of ATP (6). Thus, the signal reduction in the
absence of exogenous nucleotides or under nucleotide-depleting
conditions (Fig. 5A) is not due to affinity changes but
rather is due to inactivation of TAP complexes that result in an
irreversible loss of peptide binding function. The results shown in
Fig. 5A suggest that ATP and ADP enhanced the stability of
both TAP1·TAP2 and TAP1·TAP2-tapasin complexes.
To examine the stabilizing effect of tapasin, the ratios of quenching
signals obtained after 34 °C incubations were expressed as a ratio
relative to the signal obtained with untreated (4 °C incubated)
microsomes for each of the conditions (no exogenous nucleotide, ATP,
ADP, or apyrase) (Fig. 5B). In the absence of added
nucleotide, microsomes that express TAP1·TAP2 alone lose their
ability to bind peptides after incubation at 34 °C. Thus the average
ratio (34/4) was 0.06 ± 0.04 over many independent experiments.
However in the presence of tapasin, TAP complexes retained their
ability to bind peptides after incubation at 34 °C. The average
ratio (34/4) of quenching amplitudes for the TAP1-eGFP·TAP2 complexes
were in the range of 0.29 ± 0.09. In the presence of ATP, the
observed ratio for the TAP1·TAP2 complex was 0.36 ± 0.11, whereas it was 0.62 ± 0.09 for TAP1·TAP2-tapasin complexes. In the presence of ADP, the ratio was 0.38 ± 0.07 for TAP1·TAP2
compared with 0.56 ± 0.1 for TAP1·TAP2-tapasin. Under
conditions of depleted nucleotides (apyrase treatment), the ratio was
0.09 ± 0.05 for TAP1·TAP2, whereas the presence of tapasin
increased this ratio by nearly 2-fold (0.21 ± 0.06). The data
shown in Fig. 5 represent average ratios from many independent
experiments, each done in duplicate. Within individual experiments,
consistently higher 34/4 ratios were obtained (under all nucleotide
conditions) with microsomes expressing TAP1·TAP2-tapasin compared
with microsomes expressing TAP1·TAP2 alone, but ratio differences
were most pronounced under the conditions in which neither exogenous
nucleotide nor apyrase was present. Under these conditions low levels
of endogenous nucleotides might be present that synergize with tapasin
to enhance TAP complex stability.
We investigated the thermolability of the peptide binding site (Fig. 5)
to determine whether it was accompanied by TAP1·TAP2 dissociation and
whether tapasin was still associated with the TAP proteins upon
incubation of the proteins at 34 °C. We used metabolic labeling and
co-immunoprecipitation analyses to address these questions. TAP1 and
TAP2 are not well resolved by SDS-PAGE; however, the TAP1 fusion
protein, TAP1-eGFP, was well separated from TAP2. Insect cells were
infected with viruses encoding the TAP1-eGFP·TAP2 combination or the
TAP1-eGFP·TAP2-tapasin combination and metabolically labeled 60-h
post-infection. 72 h post-infection, the labeled cells were
centrifuged and incubated in peptide binding assay buffer (lacking
nucleotides and Mg2+) for 1 h at 4 or 34 °C. At
these late time points post-infection, most of the cells are permeable,
and thus, the TAP proteins were exposed to the "no-added
nucleotide" conditions of Fig. 5. Cells were lysed, and TAP and
tapasin were immunoprecipitated with anti-GFP, anti-TAP2 antiserum, and
anti-tapasin. Proteins were separated by SDS-PAGE, and radiolabeled
bands were visualized by phosphorimaging analyses (Fig.
6).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 6.
Thermostability of TAP1·TAP2 and
TAP1·TAP2-tapasin interactions. A, metabolically labeled
cells infected with viruses encoding either TAP1-eGFP·TAP2 or
TAP1-eGFP·TAP2-tapasin were incubated at 4 or 34 °C in peptide
binding assay buffer as indicated. Cells were subsequently lysed, and
proteins were immunoprecipitated (IP) with antibodies
against anti-GFP (top panel), anti-TAP2 antiserum
(middle panel), and anti-tapasin (bottom panel).
Proteins were visualized by SDS-PAGE and phosphorimaging analysis.
B, intensity ratios (34/4) of immunoprecipitated TAP1
(first and third bars) or TAP2 (second
and fourth bars) were quantified in the anti-GFP
(first bar)-, anti-TAP2 (second bar)-, or
anti-tapasin (third and fourth bars)-based
immunoprecipitations of cells expressing TAP1 and TAP2 alone or TAP1,
TAP2, and tapasin as indicated. The data shown here are from a single
immunoprecipitation analysis but are representative of two independent
experiments.
|
|
TAP1 and TAP2 could be co-immunoprecipitated after a 34 °C
incubation (Fig. 6A, middle panel,
lane 2) even in the absence of tapasin, although the
expression of both proteins were significantly reduced. Under the
infection conditions used for the analysis, TAP2 appears to be
expressed in greater than 3-fold excess relative to TAP1 based upon
intensities of the TAP1-eGFP and TAP2 bands; thus, most of the TAP1
would be expected to be in complex with TAP2. Nevertheless, TAP1
signals were reduced after the 34 °C incubations (Fig.
6A, top and middle panels; lane
1 compared with lane 2), indicating that TAP proteins
in TAP1·TAP2 complexes were susceptible to inactivation/degradation
upon 34 °C incubation. However, the 34 °C incubation resulted in
TAP1·TAP2 intensity ratios approaching stoichiometric levels (Fig.
6A, middle panel, lane 1 compared with
lane 3), indicating that TAP1·TAP2 complexes were less
susceptible to thermal inactivation compared with the free subunits. It
is thus possible that the thermolability of the peptide binding site is
coincident with a more rapid dissociation of TAP1·TAP2 complexes at
higher temperatures.
Tapasin could be co-immunoprecipitated with both subunits after the
34 °C incubation (Fig. 6A, bottom panel;
second lane). Thus, consistent with enhanced thermostability
of the peptide binding site of TAP1·TAP2 complexes in the presence of
tapasin, tapasin association with the TAP subunits was maintained upon 34 °C incubation. We quantified levels of thermostable TAP1 and TAP2
in the presence or absence of tapasin, as assessed by
immunoprecipitations with anti-GFP and anti-TAP2, respectively. The
analysis revealed a significant increase in the levels of thermostable
TAP1 and TAP2 in the presence of tapasin; however, the effect on TAP1
was more pronounced than that on TAP2 (Fig. 6B,
first and second bars). We also quantified levels
of thermostable TAP1 and TAP2 in the anti-tapasin based
immunoprecipitation (Fig. 6B, third and
fourth bars). Strikingly, these analyses indicated that
there was almost no change in TAP1 levels upon incubation at 34 °C
and that there was only a 25% reduction in TAP2 levels (after
normalizing for the small reduction in immunoprecipitable tapasin)
(Fig. 6B, bars 3 and 4, respectively).
Thus, the tapasin-associated populations of each TAP subunit appear to
have significantly higher thermostability compared with the
corresponding total populations. Because TAP1 is expected to be largely
in complex with TAP2 in the analyses shown in Fig. 6, it is possible
that the more pronounced effect of tapasin on TAP1 thermostability
compared with TAP2 thermostability (Fig. 6B) is a
consequence of more stable interaction of tapasin with TAP1·TAP2
complexes compared with the free subunits. Tapasin interaction with the
TAP1·TAP2 complex could reduce TAP complex dissociation and the
consequent more rapid inactivation. However, tapasin also appears to be
capable of stabilizing free TAP2 to some extent as 75% of
tapasin-associated TAP2 is stable upon 34 °C incubation (Fig.
6B, last bar).
 |
DISCUSSION |
Earlier studies in which rat TAP1 and TAP2 were transfected into
the TAP-deficient human T2 cell line showed that calreticulin, tapasin,
and MHC class I molecules associated with TAP1 when expressed in the
absence of TAP2 or with TAP2 expressed in the absence of TAP1 (although
the efficiency of association was lower with the TAP1 transfectants
compared with the TAP2 transfectants) (26, 27). Although these studies
suggested that tapasin could interact with both TAP subunits, the
presence of other co-precipitating proteins (calreticulin, MHC class I)
made it difficult to previously unambiguously attribute the observed
associations to the occurrence of tapasin interactions with both
subunits of the TAP transporter. Indeed other experiments indicate the
possibility of direct TAP-class I interaction (28). Because insect
cells lack all the specialized components of the MHC class I antigen
presentation pathway, we could define interactions between specific
components of the TAP complex by infecting cells with baculoviruses
encoding the appropriate constructs. Metabolic labeling and
co-immunoprecipitation analyses revealed that both TAP1 and TAP2
independently co-precipitated with tapasin (Fig. 1). Likewise, the
NBD-exchanged TAP chimeras T1MT2C and T2MT1C also interacted with
tapasin (Fig. 1). Constructs encoding just the MSRs of TAP1 and TAP2
associated with each other as well as with tapasin. Taken together, the
interaction analyses suggest that tapasin interacts with the
membrane-spanning domains of both TAP1 and TAP2.
What are possible functional consequences of tapasin interaction with
the membrane-spanning regions of both TAP1 and TAP2? The primary
TAP1·TAP2 interaction interface appears to be located within the
membrane-spanning regions of TAP1 and TAP2 (Fig. 2). By interacting
with both TAP1 and TAP2 (Fig. 1), tapasin appears to stabilize a
functional TAP1·TAP2 complex (Fig. 5). In Drosophila SC-2
cells transfected with different components of the MHC class I antigen
presentation pathway, the presence of murine tapasin increased the
amount of murine TAP2 that co-precipitated with TAP1 (29). These
observations taken together with our present results (Fig.
6B) suggest that tapasin stabilizes both TAP subunits but
may interact more effectively with the TAP1·TAP2 complex compared with the isolated subunits. It will be of interest to establish whether
tapasin has independent binding sites in its structure for both TAP1
and TAP2.
A putative function assigned to tapasin is that of editing the MHC
class I peptide repertoire and promoting the binding of high affinity
peptides that results in MHC class I complexes of higher stability in
the presence of tapasin (for review, see Ref. 15). It was thus also of
interest to ask whether tapasin might have an effect on altering the
repertoire of peptides that could associate with TAP1·TAP2 complexes.
If tapasin promoted the binding of low affinity peptides to TAP
complexes, tapasin could enhance the range of peptides that are
translocated and, thus, available for assembly with MHC class I
molecules. We studied the binding of two different class I-specific
peptides to TAP complexes, one of which was a high affinity peptide and
the second, a moderate affinity peptide. We observed only 2-4-fold
differences in the derived KD values for peptide
binding to TAP1·TAP2 complexes compared with TAP1·TAP2-tapasin
complexes (Fig. 4). Although it is possible that other peptide
sequences will be identified that are more profoundly influenced in
their binding to TAP complexes by the presence of tapasin, our present
analyses suggest that tapasin is unlikely to alter the repertoire of
TAP-translocatable peptides.
The peptide binding site of TAP1·TAP2 complexes is thought to reside
in cytoplasmic loops that connect the membrane-spanning domains of TAP1
and TAP2 (for review, see Ref. 3). Residues implicated in peptide
binding are contained within the T1M/T2M constructs, which associate
with tapasin. It is likely that tapasin interactions with the TAP
subunits introduce small conformational alterations into the peptide
binding site of TAP1·TAP2 complexes that result in the observed
reduction in the peptide binding affinity in the presence of tapasin
(Fig. 4). The peptide binding affinity measurements reported here
correspond to the "resting state" of TAP1·TAP2 complexes. We
cannot presently assess whether these tapasin-induced changes in
peptide binding affinity by TAP1·TAP2 complexes in the resting state
will translate to more profound differences in "transition state"
conformations of TAP complexes during a transport cycle. A better
understanding of different conformational states of TAP complexes will
be required to address that question.
Our present studies with tapasin and previous studies with nucleotides
(6) indicate that neither tapasin nor nucleotides per se are
required for high affinity peptide binding to TAP complexes (Fig. 5).
However, nucleotides are critical for maintaining TAP complex stability
at physiological temperatures (Refs. 7 and 8 and Fig. 5). Using peptide
binding assays to quantify structurally intact TAP complexes, we
compared the effects of both tapasin and nucleotides in maintaining TAP
complex stability (Fig. 5). TAP complexes containing tapasin were
reproducibly more resistant to inactivation upon 34 °C incubation
compared with TAP complexes that lacked tapasin (Fig. 5B).
Nucleotides markedly enhanced the stability of both TAP1·TAP2
complexes as well as of TAP1·TAP2-tapasin complexes. The presence of
tapasin conferred enhanced stability to TAP complexes in the presence
of nucleotides, but the stabilizing effect of tapasin was most apparent
at low nucleotide concentrations (no exogenous nucleotide) (Fig. 5). We
suggest that the observed effect of tapasin on TAP1·TAP2 structural
stability (Figs. 5 and 6) might account for the observations of
enhanced TAP expression levels in the presence of tapasin in human and
mouse cells (14, 25). In the insect cell system, the effects of tapasin
on TAP protein expression levels were more difficult to assess under conditions of competing infections with multiple viruses. In 721.220 cells, the human tapasin-deficient cell line, TAP1 protein expression levels were increased by 2.5-3-fold upon transfection with tapasin (14). Consistent with the increase in TAP expression, there was an
~3-fold increase in peptide binding as well as translocation in
tapasin-expressing cells compared with tapasin-deficient cells. Similar
functional effects of tapasin were observed in cells derived from
tapasin-deficient mice, with the extent of the effect showing a
cell-type dependence. Murine tapasin may have a much larger effect on
murine TAP expression levels in some cell types compared with the
relatively small (2.5-3-fold) effects of human tapasin on human TAP
expression levels in the Epstein-Barr virus-transformed 721.220 cells
(25, 30). In the absence of tapasin, the higher levels of inactive TAP
complexes that we observe in the in vitro assays at 34 °C
(Fig. 5) as well as the lower levels of thermostable TAP subunits (Fig.
6) might translate in vivo to a greater proportion of TAP
complexes that are targeted for degradation. The extent of this effect
might be cell type-specific and TAP species-specific and likely to be
dependent on the inherent stability of particular TAP subunits.
In summary, our studies demonstrate the binding of tapasin to both TAP
subunits, most likely to residues contained within the
membrane-spanning regions of both TAP1 and TAP2. Complex formation with
tapasin appears to induce conformational alterations in the peptide
binding site of TAP complexes without altering the specificity of
peptide binding. These conformational changes appear to slightly decrease rather than increase the peptide binding affinities of TAP1·TAP2 complexes. Nucleotide binding to the TAP NBD has a marked influence on TAP complex stability at physiological temperatures as
previously described (8), an important consideration in interpreting
the effects of TAP NBD mutants with reduced nucleotide binding
affinities. Tapasin enhances the structural stability of the peptide
binding site of TAP1·TAP2 complexes both in the presence and absence
of nucleotides. Finally, tapasin interactions with the TAP subunits
persist upon incubation of the complexes at near-physiological
temperatures, and tapasin enhances the thermostability of both TAP subunits.
 |
ACKNOWLEDGEMENTS |
We thank Alero Fregene for generating the
tapasin-encoding baculovirus and other technical assistance early
in the project. We thank Dr. Ping Wang for the tapasin cDNA and Dr.
Robert Trowsdale for the human TAP1 and TAP2 cDNAs. We thank Dr.
Robert Tampé for the baculoviruses encoding TAP1 and TAP2 and the
148.3 antibody, Dr. Peter Cresswell for the anti-tapasin antiserum, and
Dr. M. J. Androlewicz for the anti-TAP1 and anti-TAP2 antisera. We
are grateful to Dr. R. Neubig for use of the PTI fluorimeter. We thank the University of Michigan Biomedical Research Core facilities for
peptide synthesis and purification, the University of Michigan hybridoma core for 435.3 ascites fluids, the Cell Biology laboratories for use of computer resources, the National Cell Culture Center for
tapasin amplification, and the University of Michigan Reproductive Sciences Program for peptide iodination.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
(NIH) Grant AI44115-03 (to M. R.) and by an NIH Rheumatic Disease Core Center Grant AR48310-02 (to the University of Michigan).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Microbiology
and Immunology 5641 Medical Science Bldg. II, University of Michigan
Medical School, Ann Arbor, MI 48109-0620. Tel.: 734-647-7752: Fax:
734-764-3562; E-mail: malinir@umich.edu.
Published, JBC Papers in Press, September 3, 2002, DOI 10.1074/jbc.M207128200
2
P. E. Lapinski and M. Raghavan, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
MHC, major
histocompatibility complex;
ER, endoplasmic reticulum;
TAP1, transporter associated with antigen-processing subunit 1;
TAP2, transporter associated with antigen-processing subunit 2;
NBD, nucleotide binding domain;
MSR, membrane-spanning region;
T1MT2C, a
chimeric protein containing residues 1-541 of human TAP1 and 507-686
of human TAP2;
T2MT1C, a chimeric protein containing residues 1-506 of
human TAP2, residues 542-748 of human TAP1, and a C-terminal
hexahistidine tag;
T1M, residues 1-471 of human TAP1 with an
N-terminal AU1 epitope tag;
T2M, residues 1-432 of human TAP2 with an
N-terminal AU5 epitope tag;
T1Ctr, residues 472-748 of human TAP1
with a C-terminal hexahistidine tag;
T2Ctr, residues 433-686 of human
TAP2 with a C-terminal Myc epitope tag;
TAP1-eGFP, a TAP1 and enhanced
green fluorescent protein fusion construct.
 |
REFERENCES |
| 1.
|
Pamer, E.,
and Cresswell, P.
(1998)
Annu. Rev. Immunol.
16,
323-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Abele, R.,
and Tampe, R.
(1999)
Biochim. Biophys. Acta
1461,
405-419[Medline]
[Order article via Infotrieve]
|
| 3.
|
Momburg, F.,
and Hammerling, G. J.
(1998)
Adv. Immunol
68,
191-256[Medline]
[Order article via Infotrieve]
|
| 4.
|
Cresswell, P.,
Bangia, N.,
Dick, T.,
and Diedrich, G.
(1999)
Immunol. Rev.
172,
21-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Androlewicz, M. J.,
and Cresswell, P.
(1994)
Immunity
1,
7-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Lapinski, P. E.,
Neubig, R. R.,
and Raghavan, M.
(2001)
J. Biol. Chem.
276,
7526-7533[Abstract/Free Full Text]
|
| 7.
|
Saveanu, L.,
Daniel, S.,
and van Endert, P. M.
(2001)
J. Biol. Chem.
276,
22107-22113[Abstract/Free Full Text]
|
| 8.
|
van Endert, P. M.
(1999)
J. Biol. Chem.
274,
14632-14638[Abstract/Free Full Text]
|
| 9.
|
Neefjes, J. J.,
Momburg, F.,
and Hammerling, G. J.
(1993)
Science
261,
769-771[Abstract/Free Full Text]
|
| 10.
|
Li, S.,
Sjogren, H. O.,
Hellman, U.,
Pettersson, R. F.,
and Wang, P.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8708-8713[Abstract/Free Full Text]
|
| 11.
|
Ortmann, B.,
Copeman, J.,
Lehner, P. J.,
Sadasivan, B.,
Herberg, J. A.,
Grandea, A. G.,
Riddell, S. R.,
Tampé, R.,
Spies, T.,
Trowsdale, J.,
and Cresswell, P.
(1997)
Science
277,
1306-1309[Abstract/Free Full Text]
|
| 12.
|
Sadasivan, B.,
Lehner, P. J.,
Ortmann, B.,
Spies, T.,
and Cresswell, P.
(1996)
Immunity
5,
103-114[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Bangia, N.,
Lehner, P. J.,
Hughes, E. A.,
Surman, M.,
and Cresswell, P.
(1999)
Eur. J. Immunol.
29,
1858-1870[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Lehner, P. J.,
Surman, M. J.,
and Cresswell, P.
(1998)
Immunity
8,
221-231[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Grandea, A. G., III,
and Van Kaer, L.
(2001)
Trends Immunol.
22,
194-199[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Meyer, T. H.,
van Endert, P. M.,
Uebel, S.,
Ehring, B.,
and Tampe, R.
(1994)
FEBS Lett.
351,
443-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Arora, S.,
Lapinski, P. E.,
and Raghavan, M.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
7241-7246[Abstract/Free Full Text]
|
| 18.
|
Lapinski, P. E.,
Miller, G. G.,
Tampe, R.,
and Raghavan, M.
(2000)
J. Biol. Chem.
275,
6831-6840[Abstract/Free Full Text]
|
| 19.
|
Androlewicz, M. J.,
Anderson, K. S.,
and Cresswell, P.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9130-9134[Abstract/Free Full Text]
|
| 20.
|
van Endert, P. M.,
Tampe, R.,
Meyer, T. H.,
Tisch, R.,
Bach, J. F.,
and McDevitt, H. O.
(1994)
Immunity
1,
491-500[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Neumann, L.,
and Tampe, R.
(1999)
J. Mol. Biol.
294,
1203-1213[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Vos, J. C.,
Spee, P.,
Momburg, F.,
and Neefjes, J.
(1999)
J. Immunol.
163,
6679-6685[Abstract/Free Full Text]
|
| 23.
|
Li, S.,
Paulsson, K. M.,
Chen, S.,
Sjogren, H. O.,
and Wang, P.
(2000)
J. Biol. Chem.
275,
1581-1586[Abstract/Free Full Text]
|
| 24.
|
Cheng, Y.,
and Prusoff, W. H.
(1973)
Biochem. Pharmacol
22,
3099-3108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Grandea, A. G., III,
Golovina, T. N.,
Hamilton, S. E.,
Sriram, V.,
Spies, T.,
Brutkiewicz, R. R.,
Harty, J. T.,
Eisenlohr, L. C.,
and Van Kaer, L.
(2000)
Immunity
13,
213-222[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Antoniou, A. N.,
Ford, S.,
Pilley, E. S.,
Blake, N.,
and Powis, S. J.
(2002)
Immunology
106,
182-189[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Powis, S. J.
(1997)
Eur. J. Immunol.
27,
2744-2747[Medline]
[Order article via Infotrieve]
|
| 28.
|
Lauvau, G.,
Gubler, B.,
Cohen, H.,
Daniel, S,
Caillat-Zucman, S.,
and van Endert, P. M.
(1999)
J. Biol. Chem.
274,
31349-31358[Abstract/Free Full Text]
|
| 29.
|
Schoenhals, G. J.,
Krishna, R. M.,
Grandea, A. G., III,
Spies, T.,
Peterson, P. A.,
Yang, Y.,
and Fruh, K.
(1999)
EMBO J.
18,
743-753[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Momburg, F.,
and Tan, P.
(2002)
Mol. Immunol.
39,
217-233[CrossRef][Medline]
|